Indapamide sustained release: A review of its use in the treatment of hypertension

Drugs

Volumn 66, Issue 2, 2006, Pages 257-271

  Robinson, Dean M ^a   Wellington, Keri ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Hypertension; Indapamide SR; Left ventricular hypertrophy; Microalbuminuria; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; METOLAZONE; PRETANIX; URIC ACID;

ANTIHYPERTENSIVE ACTIVITY; BACKACHE; BLOOD PRESSURE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DIURETIC ACTIVITY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY CLEARANCE; META ANALYSIS; MICROALBUMINURIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; REVIEW; STATISTICAL SIGNIFICANCE; SUSTAINED RELEASE PREPARATION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; DIURETICS; HUMANS; HYPERTENSION; INDAPAMIDE;

ANIMALIA;

EID: 32244449222     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200666020-00011     Document Type: Review

References (51)

1. World Health Organization. The World Health Report 2002. Reducing risks, promoting healthy life [online]. Available from URL: http://www.who.int/whr/ 2002/en/index.html [Accessed 2004 Jun 13]
2. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990 Apr 7; 335 (8693): 827-38
3. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004 Mar; 18 (3): 139-85
4. World Health Organization International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 Nov; 21 (11): 1983-92
5. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21 (6): 1011-53
6. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003 Dec; 42 (6): 1206-52
7. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997 Nov 24; 157: 2413-46
8. Chaffman M, Heel RC, Brogden RN, et al. Indapamide: a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1984 Sep; 28 (3): 189-235
9. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996 1996; 77 (6): 12-16b
10. Campbell DB, Brackman F. Cardiovascular protective properties of indapamide. Am J Cardiol 1990 May 2; 65: 11-27H
11. Molyneaux LM, Willey KA, Yue DK. Indapamide is as effective as captopril in the control of microalbuminuria in diabetes. J Cardiovasc Pharmacol 1996 Mar; 27 (3): 424-7
12. Carey PA, Sheridan DJ, de Cordoue A, et al. Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis. Am J Cardiol 1996; 77 (6): 17-19b
13. Damien G, Huet de Barochez B, Schiavi P. Galenic development and pharmacokinetic profile of indapamide sustained release 1.5mg. Clin Pharmacokinet 1999; 37 (Suppl. 1): 13-9
14. Schaeffer P, Vigne P, Frelin C, et al. Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol 1990 Jul 17; 182 (3): 503-8
15. Bataillard A, Schiavi P, Sassard J. Pharmacological properties of indapamide: rationale for use in hypertension. Clin Pharmacokinet 1999; 37 (Suppl. 1): 7-12
16. Pickkers P, Garcha RS, Schachter M, et al. Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide. Hypertension 1999 Apr; 33 (4): 1043-8
17. Pruss T, Wolf PS. Preclinical studies of indapamide, a new 2-methylindoline antihypertensive diuretic. Am Heart J 1983 Jul; 106 (1 Pt 2): 208-11
18. Mironneau J, Savineau JP, Mironneau C. Effect of indapamide on the electromechanical properties of rat myometrium and rat portal vein. J Pharmacol Exp Ther 1986 Feb; 236 (2): 519-25
19. Thomas JR. A review of 10 years of experience with indapamide as an antihypertensive agent. Hypertension 1985 Nov-Dec; 7 (6 Pt 2): II152-6 1985 Nov-Dec; 7 (6 Pt 2): II152-156
20. Servier Laboratories Ltd. Natrilix SR [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2005 May 12]
21. Calder JA. Mechanism of antihypertensive action of thiazide diuretics and related drugs: direct vascular effects. J Drug Dev 1992 Apr; 4 (4): 189-98
22. Rendu F, Bachelot C, Molle D, et al. Indapamide inhibits human platelet aggregation in vitro: comparison with hydrochlorothiazide. J Cardiovasc Pharmacol 1993; 22 (Suppl. 6): S57-63
23. Kyncl J, Oheim K, Seki T, et al. Antihypertensive action of indapamide: comparative studies in several experimental models. Arzneimittelforschung 1975 Oct; 25 (10): 1491-5
24. Breugnot C, Iliou JP, Privat S, et al. In vitro and ex vivo inhibition of the modification of low-density lipoprotein by indapamide. J Cardiovasc Pharmacol 1992 Sep; 20 (3): 340-7
25. Acchiardo SR, Skoutakis VA. Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment. Am Heart J 1983 Jul; 106 (1 Pt 2): 237-44
26. Ganado P, Ruiz E, Del Rio M, et al. Growth inhibitory activity of indapamide on vascular smooth muscle cells. Eur J Pharmacol 2001 Sep 28; 428 (1): 19-27
27. Chillon JM, Baumbach GL. Effects of indapamide, a thiazide-like diuretic, on structure of cerebral arterioles in hypertensive rats. Hypertension 2004 May; 43 (5): 1092-7
28. Böcker W, Hupf H, Grimm D, et al. Effects of indapamide in rats with pressure overload left ventricular hypertrophy. J Cardiovasc Pharmacol 2000 Oct; 36 (4): 481-6
29. Ambrosioni E, Safar M, Degaute JP, et al. on behalf of the European study group. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. J Hypertens 1998 Nov; 16 (11): 1677-84
30. Emeriau JP, Knauf H, Pujadas JO, et al. A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001 Feb; 19 (2): 343-50
31. Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000 Oct; 18 (10): 1465-75
32. London GM, Schmieder R, Calvo C, et al. on behalf of the X-CELLENT study investigators. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT pharmastudy. Am J Hypertens 2006 Jan; 19 (113-21)
33. Marre M, Garcia Puig J, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertens 2004 Aug; 22 (8): 1613-22
34. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies. Drug Saf 2001; 24 (15): 1155-65
35. Leonetti G, Emeriau JP, Knauf H, et al. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Curr Med Res Opin 2005 Jan; 21 (1): 37-46
36. Greenberg A. Diuretic complications. Am J Med Sci 2000 Jan; 319 (1): 10-24
37. Schiavi P, Jochemsen R, Guez D. Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. Fundam Clin Pharmacol 2000 Mar-Apr; 14: 139-46
38. Servier Laboratories (NZ) Ltd. Data Sheet. Natrilix SR indapamide hemihydrate 1.5 mg [online]. Available from URL: http://www.medsafe.govt.nz/ Profs/Datasheet/n/NatrilixSRtab.htm [Accessed 2005 Jun 9]
39. Caruso FS, Szabadi RR, Vukovich RA. Pharmacokinetics and clinical pharmacology of indapamide. Am Heart J 1983 Jul; 106 (1 Pt 2): 212-20
40. Leonetti G. Clinical positioning of indapamide sustained release 1.5mg in management protocols for hypertension. Drugs 2000; 59 (Suppl. 2): 27-38
41. Füsgen I, Schütz D. Use of indapamide SR in elderly patients in general practice: results of a prospective study of 3034 elderly multimorbid patients [in German]. Eur J Ger 2001; 3 (4): 196-200
42. British National Formulary. Available from URL: http://www.bnf.org [Accessed 2005 Jun 1]
43. World Health Organization. The World Health Report 2003: shaping the future [online]. Available from URL: http://www.who.int/whr/2003 [Accessed 2005 Sep 9]
44. Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998 Jun 13; 351 (9118): 1755-62
45. Andersson OK, Almgren T, Persson B, et al. Survival in treated hypertension: follow up study after two decades. BMJ 1998 Jul 18; 317 (7152): 167-71
46. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 Nov 8; 362 (9395): 1527-35
47. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun 19; 363 (9426): 2022-31
48. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18; 288 (23): 2981-97
49. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000 Apr 19; 283 (15): 1967-75
50. Writing Group of the American Society of Hypertension. Medical experts redefine hypertension. Writing group urges expansion of the definition of hypertension: move paves the way for new avenues in disease management and research efforts [media release] [online]. Available from URL: http://www.ash-us.org/annual_meeting/2005/press/0514057.htm [Accessed 2005 Jun 10]
51. Bulpitt C, Fletcher A, Beckett N, et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging 2001; 18 (3): 151-64